Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D et al (2010) Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 57:804–814
Oyelade BO, Jemilohun AC, Aderibigbe SA (2016) Prevalence of erectile dysfunction and possible risk factors among men of South-Western Nigeria: a population based study. Pan Afr Med J 24:124
Sathyanarayana RT, Darshan MS, Tandon A (2015) An epidemiological study of sexual disorders in south Indian rural population. Indian J Psychiatry 57:150–157
Ramezani MA, Ahmadi K, Ghaemmaghami A, Marzabadi EA, Pardakhti F (2015) Epidemiology of sexual dysfunction in Iran: a systematic review and meta-analysis. Int J Prev Med 6:43
Zhang Z, Li Z, Yu Q, Wu C, Lu Z et al (2015) The prevalence of and risk factors for prostatitis-like symptoms and its relation to erectile dysfunction in Chinese men. Andrology 3:1119–1124
Ayta IA, McKinlay JB, Krane RJ (1999) The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 84:50–56
Ventimiglia E, Capogrosso P, Montorsi F, Salonia A (2016) The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. Expert Opin Drug Saf 15:141–152
Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A (2013) An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother 14:1333–1344
Patel CK, Bennett N (2016) Advances in the treatment of erectile dysfunction: what’s new and upcoming? F1000Res 5:369–375
Raheem AA, Kell P (2009) Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil. Patient Prefer Adherence 3:99–104
Seftel AD (2002) Challenges in oral therapy for erectile dysfunction. J Androl 23:729–736
Evans JD, Hill SR (2015) A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil. Patient Prefer Adherence 9:1159–1164
Yuan J, Zhang R, Yang Z, Lee J, Liu Y et al (2013) Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 63:902–912
Berner MM, Kriston L, Harms A (2006) Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. Int J Impot Res 18:229–235
Chen L, Staubli SE, Schneider MP, Kessels AG, Ivic S et al (2015) Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol 68:674–680
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
Bai WJ, Li HJ, Jin JJ et al (2017) A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction. Asian J Androl 19(4):500–504
Buvat J, Buttner H, Hatzimouratidis K, Vendeira PA, Moncada I et al (2013) Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med 10:1592–1602
Conaglen HM, Conaglen JV (2008) Investigating women’s preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners’ preference study. J Sex Med 5:1198–1207
Eardley I, Mirone V, Montorsi F, Ralph D, Kell P et al (2005) An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 96:1323–1332
Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P et al (2003) A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 25:2709–2723
Hatzimouratidis K, Buvat J, Buttner H, Vendeira PA, Moncada I et al (2014) Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. Int J Impot Res 26:223–229
Rubio-Aurioles E, Porst H, Kim ED, Montorsi F, Hackett G et al (2012) A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 9:1418–1429
Tolra JR, Campana JM, Ciutat LF, Miranda EF (2006) Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 3:901–909
von Keitz A, Rajfer J, Segal S, Murphy A, Denne J et al (2004) A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 45(499–507):507–509
Li HJ, Bai WJ, Dai YT, Xu WP, Wang CN et al (2016) An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction. Asian J Androl 18:773–779
Cairoli C, Reyes LA, Henneges C, Sorsaburu S (2014) PDE5 inhibitor treatment persistence and adherence in Brazilian men: post hoc analyses from a 6-month, prospective, observational study. Int Braz J Urol 40:390–399
Stroberg P, Murphy A, Costigan T (2003) Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 25:2724–2737
Ahn TY, Lee SW, Kim SW, Yang DY, Park NC et al (2007) Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil. Asian J Androl 9:760–770
El-Meliegy A, Rabah D, Al-Mitwalli K, Mostafa T, Hussein T et al (2013) A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction. Curr Med Res Opin 29:707–717
Taylor J, Baldo OB, Storey A, Cartledge J, Eardley I (2009) Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int 103:1392–1395
Rizio N, Tran C, Sorenson M (2012) Efficacy and satisfaction rates of oral PDE5is in the treatment of erectile dysfunction secondary to spinal cord injury: a review of literature. J Spinal Cord Med 35:219–228
Tang Z, Li D, Zhang X, Yi L, Zhu X et al (2014) Comparison of the simplified International Index of Erectile Function (IIEF-5) in patients of erectile dysfunction with different pathophysiologies. BMC Urol 14:52
Rew KT, Heidelbaugh JJ (2016) Erectile dysfunction. Am Fam Physician 94:820–827
Wang W (2011) Psychological factors involved in erectile dysfunction. Zhonghua Nan Ke Xue 17:1146–1151
Sontag A, Ni X, Althof SE, Rosen RC (2014) Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil. Int J Impot Res 26:7–12
Li G, Lan H, Liang J, Zhang C, Huang C (2017) Efficacy of tadalafil de-escalation in the treatment of psychogenic erectile dysfunction. Urol Int 98:205–209
Albertsen PC (2005) Development and validation of the self-esteem and relationship (SEAR) Questionnaire in erectile dysfunction. J Urol 173:1328
Althof SE, Corty EW, Levine SB, Levine F, Burnett AL et al (1999) EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 53:793–799
Huang SA, Lie JD (2013) Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P T 38:407–419